Tags : Urothelial Cancer

Roche and Basilea Sign a Research Collaboration to Evaluate Derazantinib

 Shots:  Basilea to conduct the P-I/II biomarker-driven clinical trial with its expected initiation in H1’2019 and Roche to provide atezolizumab for the trial  The focus of the agreement is for the onset of the trial assessing Basilea’s derazantinib in combination with Roche’s Tecentriq (atezolizumab) in patients with advanced (UC) and FGFR genomic defects  Derazantinib (BAL087, formerly ARQ 087) is […]Read More